The presence of HER3, as an allosteric activator, is required to maintain active HER2-mediated signalling [8, 9], and aberrantly intensified HER2-HER3 signalling is hence critically associated with breast carcinogenesis and tumour cell proliferation [4, 10–12]. The gene discussed is ERBB2; the disease is neoplasm.